Circulating tumor-reactive KIR + CD8 + T cells suppress anti-tumor immunity in patients with melanoma

Benjamin Y. Lu,Liliana E. Lucca,Wesley Lewis,Jiping Wang,Catarina V. Nogueira,Sebastian Heer,Violeta Rayon-Estrada,Pierre-Paul Axisa,Sarah M. Reeves,Nicholas C. Buitrago-Pocasangre,Giang H. Pham,Mina L. Kojima,Wei Wei,Lilach Aizenbud,Antonietta Bacchiocchi,Lin Zhang,Joseph J. Walewski,Veronica Chiang,Kelly Olino,James Clune,Ruth Halaban,Yuval Kluger,Anthony J. Coyle,Jan Kisielow,Franz-Josef Obermair,Harriet M. Kluger,David A. Hafler
DOI: https://doi.org/10.1038/s41590-024-02023-4
IF: 30.5
2024-11-29
Nature Immunology
Abstract:Effective anti-tumor immunity is driven by cytotoxic CD8 + T cells with specificity for tumor antigens. However, the factors that control successful tumor rejection are not well understood. Here we identify a subpopulation of CD8 + T cells that are tumor-antigen-specific and can be identified by KIR expression but paradoxically impair anti-tumor immunity in patients with melanoma. These tumor-antigen-specific KIR + CD8 + regulatory T cells target other tumor-antigen-specific CD8 + T cells, can be detected in both the tumor and the blood, have a conserved transcriptional program and are associated with a poor overall survival. These findings broaden our understanding of the transcriptional and functional heterogeneity of human CD8 + T cells and implicate KIR + CD8 + regulatory T cells as a cellular mediator of immune evasion in human cancer.
immunology
What problem does this paper attempt to address?